| Autor: |
Alijaj N; Department of Urology, University Hospital of Zürich and University of Zürich, 8006 Zürich, Switzerland., Pavlovic B; Department of Urology, University Hospital of Zürich and University of Zürich, 8006 Zürich, Switzerland., Martel P; Department of Urology, Urology Research Unit and Urology Biobank, University Hospital of Lausanne, 1011 Lausanne, Switzerland., Rakauskas A; Department of Urology, Urology Research Unit and Urology Biobank, University Hospital of Lausanne, 1011 Lausanne, Switzerland., Cesson V; Department of Urology, Urology Research Unit and Urology Biobank, University Hospital of Lausanne, 1011 Lausanne, Switzerland., Saba K; Department of Urology, University Hospital of Zürich, 8091 Zürich, Switzerland., Hermanns T; Department of Urology, University Hospital of Zürich, 8091 Zürich, Switzerland., Oechslin P; Department of Urology, University Hospital of Zürich, 8091 Zürich, Switzerland., Veit M; Department of Urology, University Hospital of Zürich, 8091 Zürich, Switzerland., Provenzano M; Department of Urology, University Hospital of Zürich, 8091 Zürich, Switzerland., Rüschoff JH; Department of Pathology and Molecular Pathology, University Hospital of Zürich, 8091 Zürich, Switzerland., Brada MD; Department of Pathology and Molecular Pathology, University Hospital of Zürich, 8091 Zürich, Switzerland., Rupp NJ; Department of Pathology and Molecular Pathology, University Hospital of Zürich, 8091 Zürich, Switzerland.; Faculty of Medicine, University of Zürich, 8032 Zürich, Switzerland., Poyet C; Department of Urology, University Hospital of Zürich, 8091 Zürich, Switzerland., Derré L; Department of Urology, Urology Research Unit and Urology Biobank, University Hospital of Lausanne, 1011 Lausanne, Switzerland., Valerio M; Department of Urology, Urology Research Unit and Urology Biobank, University Hospital of Lausanne, 1011 Lausanne, Switzerland., Banzola I; Department of Urology, University Hospital of Zürich and University of Zürich, 8006 Zürich, Switzerland., Eberli D; Department of Urology, University Hospital of Zürich, 8091 Zürich, Switzerland. |
| Abstrakt: |
PCa screening is based on the measurements of the serum prostate specific antigen (PSA) to select men with higher risks for tumors and, thus, eligible for prostate biopsy. However, PSA testing has a low specificity, leading to unnecessary biopsies in 50-75% of cases. Therefore, more specific screening opportunities are needed to reduce the number of biopsies performed on healthy men and patients with indolent tumors. Urine samples from 45 patients with elevated PSA were collected prior to prostate biopsy, a mass spectrometry (MS) screening was performed to identify novel biomarkers and the best candidates were validated by ELISA. The urine quantification of PEDF, HPX, CD99, CANX, FCER2, HRNR, and KRT13 showed superior performance compared to PSA. Additionally, the combination of two biomarkers and patient age resulted in an AUC of 0.8196 (PSA = 0.6020) and 0.7801 (PSA = 0.5690) in detecting healthy men and high-grade PCa, respectively. In this study, we identified and validated novel urine biomarkers for the screening of PCa, showing that an upfront urine test, based on quantitative biomarkers and patient age, is a feasible method to reduce the number of unnecessary prostate biopsies and detect both healthy men and clinically significant PCa. |
